Katalog der Deutschen Nationalbibliothek

Springe direkt zu:

Katalog (Beta)

Wissensnetz

Person
Person

Person

Jochen Seufert (1964-)

Internist

Name

Jochen Seufert

Zeit

1964- (Lebensdaten)

Ort

Gerolzhofen (Geburtsort)
Deutschland

Geschlecht

männlich

Akademischer Grad bzw. Titel

Prof. Dr. med.

Beruf

Internist (charakteristischer Beruf)
Arzt

Variante

J. Seufert

Weitere Angaben

Abteilung Endokrinologie und Diabetologie im Universitätsklinikum Freiburg

Quelle

Vorlage

Datensatztyp

Person

GND-Nummer

1047316234

Datensatz-ID

1047316234

Beteiligt an

alle anzeigen

Real-Life Effectiveness of iGlarLixi (Insulin Glargine 100 U/ml and Lixisenatide) in People with Type 2 Diabetes (T2D) According to Baseline HbA1c and BMI

Kontinuierliche Glukosemessung bei Menschen mit Typ-2-Diabetes ohne intensivierte Insulintherapie: eine Standortbestimmung

Diabetes mellitus: kardiovaskuläre Risikoreduktion im Fokus

Students Diabetes Day der AG Nachwuchs der Deutschen Diabetes Gesellschaft in Potsdam-Rehbrücke – ein voller Erfolg!

Liebe Leserin, lieber Leser

Liebe Leserin, lieber Leser,

Liebe Leserin, lieber Leser,

Liebe Leserin, lieber Leser,

Auswertung biochemischer Parameter aus dem Nabelschnurserum Neugeborener von Müttern mit Gestationsdiabetes

Combination of Lenvatinib and Pembrolizumab Is an Effective Treatment Option for Anaplastic and Poorly Differentiated Thyroid Carcinoma

Effective management of recurrent Doege–Potter syndrome with somatostatin‐analogues: a case report

Einstellung zur Insulinpumpentherapie bei Menschen mit Typ-1-Diabetes sechs Monate nach Umstellung im Vergleich zu mehrfach täglichen Insulininjektionen - eine Beobachtungstudie = Attitudes towards insulin pump therapy in people with type 1 diabetes six months after switch versus multiple daily insulin injections - an observational trial

Kontinuierliche Glukosemessung bei Menschen mit Typ-2-Diabetes ohne intensivierte Insulintherapie: eine Standortbestimmung = Continuous glucose monitoring (CGM) in people with type 2 diabetes not on multiple daily injections (MDI): review of current evidence and potential future positioning

Management of pasireotide-induced hyperglycemia in patients with acromegaly: an experts’ consensus statement

Real-life effectiveness of iGlarLixi (insulin glargine 100 U/ml and lixisenatide) in people with type 2 diabetes (T2D) according to baseline HbA1c and BMI

Reduced bone mineral density is associated to post-TIPS survival of female patients with decompensated cirrhosis

Regional socioeconomic deprivation associated with the use of sodium‐glucose cotransporter‐2 inhibitors and glucagon‐like peptide‐1 receptor agonists in adults with type 2 diabetes in Germany

Verordnung von Antidiabetika und glykämische Kontrolle bei Erwachsenen mit Diabetes mellitus Typ 2 im zeitlichen Verlauf: Auswertung aus dem DPV-Register aus den Jahren 2005 bis 2021

Tirzepatid: GIP-/GLP-1-Rezeptoragonist zur Therapie des Typ-2-Diabetes – SURPASS-Studienprogramm

An analysis of DPV and DIVE registry patients with chronic kidney disease according to the finerenone phase III clinical trial selection criteria

Effectiveness and Safety of iGlarLixi (Insulin Glargine 100 U/mL Plus Lixisenatide) in Type 2 Diabetes According to the Timing of Daily Administration: Data from the REALI Pooled Analysis

Local, collaborative, stepped, and personalized care management for older people with chronic diseases – results from the randomized controlled LoChro-trial

Liebe Leserin, lieber Leser,

Liebe Leserin, lieber Leser,

Liebe Leserin, lieber Leser,

Liebe Leserin, lieber Leser,

Liebe Leserin, lieber Leser,

An analysis of DPV and DIVE registry patients with chronic kidney disease according to the finerenone phase III clinical trial selection criteria

Cardiovascular and kidney outcomes with canagliflozin according to type 2 diabetes treatment targets at baseline: data from the CANVAS Program and CREDENCE

Effectiveness and safety of iGlarLixi (Insulin Glargine 100 U/mL plus Lixisenatide) in type 2 diabetes according to the timing of daily administration: data from the REALI pooled analysis

Effects of canagliflozin on cardiovascular and kidney events in patients with chronic kidney disease with and without peripheral arterial disease: integrated analysis from the CANVAS Program and CREDENCE trial

Effekte des Duodenal-Jejunal Bypass Liner (DJBL) auf kardiovaskuläre Risiko-Biomarker bei adipösen Patient*innen mit Diabetes mellitus Typ 2 und Metabolischem Syndrom

Identification of predictive factors of diabetic ketoacidosis in type 1 diabetes using a subgroup discovery algorithm

iGlarLixi (insulin glargine 100 U/mL plus lixisenatide) is effective and well‐tolerated in people with uncontrolled type 2 diabetes regardless of age: a REALI pooled analysis of prospective real‐world data

Local, collaborative, stepped, and personalized care management for older people with chronic diseases – results from the randomized controlled LoChro-trial

Patient and physician perspectives and experiences of basal insulin titration in type 2 diabetes in the United States: cross‐sectional surveys

Patient perspectives and experiences with basal insulin titration in type 2 diabetes in the United States: a cross‐sectional survey

Tirzepatid: GIP-/GLP-1-Rezeptoragonist zur Therapie des Typ-2-Diabetes – SURPASS-Studienprogramm

Liebe Leserin, lieber Leser,

Liebe Leserin, lieber Leser,

Liebe Leserin, lieber Leser,

Liebe Leserin, lieber Leser,

Liebe Leserin, lieber Leser,

Die Glukosesenkung mit dem SGLT2-Hemmer Empagliflozin verbessert die Atheroskleroseregression in der hyperglykämischen STZ-diabetischen Maus

Disease heterogeneity of adult diabetes based on routine clinical parameters at diagnosis: results from the German/Austrian DPV registry

Mechanistic insights into the effects of empagliflozin in patients with type 2 diabetes and heart failure

Mesenchymal stem cell (MSC)-mediated survival of insulin producing pancreatic β-cells during cellular stress involves signalling via AKT and ERK1/2

PCSK9 inhibition and cholesterol homeostasis in insulin producing β-cells

Real-world‐data of 12‐month adjunct SGLT2‐inhibitor treatment in type 1 diabetes from the German/Austrian DPV registry: improved HbA1c without DKA

Real‐world data of 12‐month adjunct sodium‐glucose co‐transporter‐2 inhibitor treatment in type 1 diabetes from the German/Austrian DPV registry: Improved HbA1c without diabetic ketoacidosis

Switching the basal insulin to insulin glargine 300 u/ml in people with type 2 diabetes under basal insulin supported oral therapy – observational trial on effectiveness and safety

Effectiveness and Safety of Switching Rapid-Acting Insulins to Insulin Glulisine in Patients with Diabetes: The Observational IGLU-S Study

Effectiveness and Safety of Insulin Glulisine When Initiating Supplementary Prandial Insulin Treatment (SIT) in Insulin-Naïve Patients with Type 2 Diabetes: The Observational IGLU-SIT Study

Durch Förderung des diabetologischen Nachwuchses in der DDG exzellente Forschung und Patientenversorgung zukunftssicher aufstellen – Hellmut-Otto-Medaille 2021 - Kurzübersicht der Preisträger Annette Schürmann und Jochen Seufert

Liebe Leserin, lieber Leser,

Liebe Leserin, lieber Leser,

Combination of Lenvatinib and Pembrolizumab is an effective treatment option for anaplastic and poorly differentiated thyroid carcinoma

Effectiveness and safety of switching rapid-acting insulins to insulin glulisine in patients with diabetes: the observational IGLU-S study

Einfluss des Duodenal-Jejunal Bypass Liner (DJBL) auf die nichtalkoholische Fettlebererkrankung bei adipösen Patienten mit Diabetes mellitus Typ 2

Guidelines adherence in the prevention and management of chronic kidney disease in patients with diabetes mellitus on the background of recent European recommendations – a registry-based analysis
Hinweis

Die Betaversion beinhaltet noch nicht alle Funktionen und Informationen des Katalogs des DNB-Portals. Falls Sie Informationen vermissen oder ein Medium bestellen wollen, besuchen Sie bitte die entsprechende Seite im Katalog des DNB-Portals über folgenden Link:

DNB-Portal